Peptides DB
Research-centric peptide and protocol reference hub

Liraglutide record · updated 7h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 26 studiesJump to the evidenceCompare
What is Liraglutide used for?

Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), which is integral to glucose metabolism and appetite regulation. As a GLP-1 receptor agonist, liraglutide enhances insulin secretion in response to elevated blood glucose levels while inhibiting glucagon release, thereby contributing to lower blood sugar levels. Additionally, it slows gastric emptying and promotes feelings of fullness, which can aid in weight loss for individuals with obesity or type 2 diabetes.

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Liraglutide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 166 registered trials. It describes the research record, not a recommendation.

Identity
NameLiraglutide
Chain length—
Molecular weight3,751 Da
FormulaC172H265N43O51
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 16134956. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
RouteSubcutaneous injection
Half-life~13 hours
Time to peak8–12 hours
Duration24 hours
Extraction confidence1.00
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 21, 2026. How this works →
Research stats
Total studies26
Human / animal / cellular9 / 2 / 3
Highest trial phasePhase 3
Years covered2026
Latest study15d ago
Publication history
20262026
Research funding
344 NIH projects · $28.6M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports3,598
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

26 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Real-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.
FindingMean HbA1c decreased by 1.66 percentage points; P < 0.001.
Human2026Full text read0.80
Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.
FindingIncremental cost-effectiveness ratio of US$34,423.89/QALY for tirzepatide compared with semaglutide.
review2026Full text read0.80
Inflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.
FindingNot reported in abstract.
review2026Full text read0.70
Engineering 3'-UTR hairpin structures to modulate mRNA stability and recombinant protein production in Escherichia coli.
Findingspecific cellular fusion-protein content increased approximately 3-fold (p < 0.001, n=6)
In vitro2026Full text read0.80
Emerging Therapeutic Strategies for Infantile Obesity: A Narrative Review
Finding1.71 kg/m² BMI reduction with medication plus behavioral treatment vs behavioral treatment alone, n=4331.
review2026Full text read0.80
Prevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.
FindingHR 0.72; 95% CI 0.60-0.86 for new-onset CKD with ACEI/ARB therapy.
Human2026Full text read0.80
SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study.
FindingaHR 0.87, 95% CI 0.71-1.06 for KRT risk in full cohort.
Human2026Full text read0.80
Importance of antibody validation in detecting cell cycle regulatory protein p16 INK4A by immunohistochemistry on pancreas tissue.
FindingNot reported in abstract.
In vitro2026Full text read0.80
Adherence to the Mediterranean diet and its effects on the onset and progression of diabetic nephropathy: a systematic review.
Finding21% to 86% reduction in risk of DN with higher MD adherence.
review2026Full text read0.80
Compounded GLP-1 Drugs Remain Prevalent After Drug Shortage.
TakeawayNot reported in abstract.
—2026Title only0.10
Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.
Finding42% of centres reported that GLP-1RA therapy could be initiated by sleep physicians within the sleep clinic.
Human2026Full text read0.70
Comparative Exposure-Adjusted Adverse Reaction Reporting Rates for GLP-1-Based Therapies: An Analysis of UK MHRA Yellow Card Data and NHS Prescribing Data for England
FindingLiraglutide 1,326.64 (1,268.16–1,387.82) per million items.
review2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Liraglutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Liraglutide is discussed should be drawn from it.

Articles mentioning Liraglutide